Mironid® Limited

Catherine (Cass) Kelleher, MD, our Chief Medical Officer, Adele Rowley, our Chief Scientific Officer, and David J P Henderson, our Head of Biology were in San Diego last week at Kidney Week, organised by the American Society of Nephrology, where we presented our research on Navigating the translation of LoAc® compound efficacy in ADPKD.   This event was a great opportunity to meet with other experts from across the globe and learn more about the exciting and challenging opportunities in the kidney disease space.   To find out more about what we do at Mironid, visit: https://lnkd.in/ennSvC9K   #ADPKD #kidneydisease #raredisease #biopharma #ASN

Our Chief Executive Officer Neil Wilkie will be in Stockholm from 4-6 November attending the 30th annual BIO-Europe conference. At Mironid, we are committed to transforming the treatment landscape for patients with ADPKD and other rare diseases, and we look forward to sharing our latest insights at this event! To speak with Neil, please do get in touch via the partneringONE system. Find out more about BIO-Europe here: https://lnkd.in/dnuNZ2D #BioEurope #kidneydisease #raredisease #biopharma #biotech

The Mironid team will be in San Diego from 23-27 October attending Kidney Week, an annual scientific conference organised by the American Society of Nephrology. We look forward to presenting our research, with Catherine (Cass) Kelleher, MD, our Chief Medical Officer, Adele Rowley, our Chief Scientific Officer, and David J P Henderson, our Head of Biology, hosting an abstract presentation titled: Navigating the translation of LoAc® compound efficacy in ADPKD on 24 October from 10am to 12pm PDT as part of the poster session: Cystic Kidney Diseases: Clinical Assessment and Therapeutic Directions [PO1201-1]. We look forward to seeing you there! Find out more about Kidney Week here: https://lnkd.in/e5X2-HC #ADPKD #kidneydisease #raredisease #biopharma #ASN

David J P Henderson, Head of Biology at Mironid, was invited to speak at Cilia2024 in Dublin recently, where he presented scientific data during the first session of the conference discussing our approach for the treatment of ADPKD with patients, advocacy groups and researchers from all over the world.    This event brought together leading experts from around the globe to discuss cutting-edge developments in the field and was a fantastic opportunity to share our latest findings and connect with fellow researchers.   Find out more about what we do at Mironid here: https://lnkd.in/ennSvC9K   #cilia2024 #kidneydisease #raredisease #biopharma

Our Head of Biology David J P Henderson will be in Dublin next week at Cilia2024, the world’s largest scientific meeting for cilia and ciliopathy research running 10-13 September. David will be presenting an abstract titled: “Allosteric modulation of long-form PDE4 enzymes as a potential treatment for ADPKD” on Tuesday 10 September at 12:20 BST as part of Session 1: Cilia Therapeutics. Be sure to come along to watch his presentation! Find out more about the event here: https://cilia2024.ie/ #cilia2024 #kidneydisease #raredisease #biopharma #drugdiscovery

We did it! On Saturday, the Mironid Mudders traded in their lab coats for mud, sweat, and a whole lot of fun at Tough Mudder Scotland to raise funds and awareness for the Polycystic Kidney Disease (PKD) Charity UK (PKD) Charity. A huge well done to the team for their teamwork and determination, and a massive thank you to everyone who came to cheer us on from the sidelines and helped us raise money for the PKD Charity! Learn more about the work we do at Mironid to transform the treatment landscape for patients with ADPKD: https://lnkd.in/ekZ9-J2w  #ToughMudder #ADPKD #kidneydisease #RareDisease 

Our Lab Manager Jane Findlay recently represented Mironid at the Scientific Laboratory Show and Conference hosted by (SLS) Scientific Laboratory Supplies Ltd. Show and Conference in Nottingham. This event hosted a number of fantastic seminars ranging from lab sustainability to equipment management and was a great opportunity to connect with fellow scientists and discover the latest innovations from the top scientific tools providers. Find out more about what we do at Mironid here: https://lnkd.in/ennSvC9K #ADPKD #kidneydisease #raredisease #biopharma

The Mironid Mudders are taking on Tough Mudder Scotland on 15th June to raise funds and awareness for the Polycystic Kidney Disease (PKD) Charity UK. We'll be put through our paces – 5 km of mud and 12 hardcore obstacles – but we’re expecting teammate camaraderie to get us all over the finish line! At Mironid, we’re dedicated to developing new therapies to treat ADPKD (Autosomal Dominant Polycystic Kidney Disease) and other rare diseases. ADPKD is a debilitating inherited disease that causes cysts to form in the kidneys over time and leads to kidney damage and failure, at which point patients need dialysis or transplant. ADPKD is the most common inherited kidney disease, with 1 person in every 1,000-2,500 in the UK having ADPKD. The PKD charity is dedicated to improving the lives of individuals & families affected by PKD in the UK. They provide information, advice and personalised support as well as raising the awareness of the burden of PKD. You can donate here: https://lnkd.in/exwvJwtR ! Learn more about the Polycystic Kidney Disease Charity here: https://pkdcharity.org.uk/ #ToughMudder #ADPKD #kidneydisease #raredisease #biopharma 

We have successfully completed the project funded by Innovate UK titled: ‘Extending Mironid's PDE4 activator programme: Hyperparathyroidism as a second clinical indication’. Our findings were presented at the project close-out meeting by Caitlin Moore, one of our Biology Research Scientists, with others from our team in attendance. Read our blog to find out more about the project and the next steps: https://lnkd.in/eSgcS-gF #HPT #biopharma #drugdevelopment 

Mironid’s CSO Adele Rowley and CMO Catherine (Cass) Kelleher, MD were at the European Renal Association (ERA) Congress over the weekend. Adele gave an oral presentation entitled ‘Targeting cAMP in ADPKD by small molecule activation of long form PDE4 enzymes’ that highlighted data demonstrating that a LoAc® compound resulted in a significant reduction of cAMP levels in a model of Autosomal Dominant Polycystic Kidney Disease (ADPKD), potentially slowing disease progression, preventing the need for dialysis, and offering a potential new treatment option for ADPKD patients. We look forward to progressing a development candidate from our LoAc® programme to advance as a treatment for ADPKD.   #ERA24 #Presentation #kidneydisease #raredisease